Lack of Response to HBHA in HIV-Infected Patients with Latent Tuberculosis Infection

Scandinavian Journal of Immunology

Volumn 84, Issue 6, 2016, Pages 344-352

  Delogu, G ^a,b   Vanini, V ^a   Cuzzi, G ^a   Chiacchio, T ^a   De Maio, F ^b   Battah, B ^b   Pinnetti, C ^a   Sampaolesi, A ^a   Antinori, A ^a   Goletti, D ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; BIOLOGICAL MARKER; GAG PROTEIN; GAMMA INTERFERON; HEPARIN BINDING HAEMAGGLUTININ; ISONIAZID; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; HBHA PROTEIN, MYCOBACTERIUM TUBERCULOSIS; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; MEMBRANE PROTEIN;

ADULT; ARTICLE; BCG VACCINATION; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IN VITRO STUDY; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MYCOBACTERIUM TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS TEST KIT; PRIORITY JOURNAL; PROSPECTIVE STUDY; TUBERCULOSIS; BLOOD; CELL CULTURE; COMPLICATION; DIFFERENTIAL DIAGNOSIS; FOLLOW UP; HIV INFECTIONS; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PROGNOSIS; RISK; TUBERCULOSIS, PULMONARY;

ADULT; BACTERIAL PROTEINS; BIOMARKERS; CELLS, CULTURED; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOLLOW-UP STUDIES; HIV ANTIGENS; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; INTERFERON-GAMMA; LATENT TUBERCULOSIS; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE PROTEINS; MYCOBACTERIUM TUBERCULOSIS; PROGNOSIS; PROSPECTIVE STUDIES; RISK; TUBERCULOSIS, PULMONARY;

EID: 85006968480     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12493     Document Type: Article

References (47)

1. World Health Organization. Global Tuberculosis Report 2015, 2015.
2. Pokrovskiy V. HIV epidemic in Russia and neighbouring countries. J Int AIDS Soc 2014;17 (Suppl. 3):19502.
3. Podlekareva DN, Efsen AM, Schultze A et al. Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study. Lancet HIV 2016;3:e120–31.
4. Furin J, Akugizibwe P, Ditiu L, Gray G, Palmero D, Zaidi S. No one with HIV should die from tuberculosis. Lancet 2015;386:e48–50.
5. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010:CD000171.
6. Goletti D, Sanduzzi A, Delogu G. Performance of the tuberculin skin test and interferon-gamma release assays: an update on the accuracy, cutoff stratification, and new potential immune-based approaches. J Rheumatol Suppl 2014;91:24–31.
7. Delogu G, Goletti D. The spectrum of tuberculosis infection: new perspectives in the era of biologics. J Rheumatol Suppl 2014;91:11–6.
8. Goletti D, Raja A, Syed Ahamed KB et al. Is IP-10 an accurate marker for detecting M. tuberculosis-specific response in HIV-infected persons? PLoS ONE 2010;5:e12577.
9. Vincenti D, Carrara S, Butera O et al. Response to region of difference 1 (RD1) epitopes in human immunodeficiency virus (HIV)-infected individuals enrolled with suspected active tuberculosis: a pilot study. Clin Exp Immunol 2007;150:91–8.
10. Chiacchio T, Petruccioli E, Vanini V et al. Polyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patients. J Infect 2014;69:533–45.
11. Rangaka MX, Wilkinson KA, Glynn JR et al. Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012;12:45–55.
12. Sane SM, Parracino MP, Mammone A et al. Immune status and serial Quantiferon-TB gold in-tube screening for latent mycobacterium tuberculosis infection among HIV-infected persons in a country with a low tuberculosis incidence. J Infect Dis 2015;211:1852–3.
13. Sester M, van Leth F, Bruchfeld J et al. Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. Am J Respir Crit Care Med 2014;190:1168–76.
14. Goletti D, Petruccioli E, Joosten SA, Ottenhoff TH. Tuberculosis biomarkers: from diagnosis to protection. Infect Dis Rep 2016;8:24–32.
15. Goletti D, Butera O, Bizzoni F, Casetti R, Girardi E, Poccia F. Region of difference 1 antigen-specific CD4+ memory T cells correlate with a favorable outcome of tuberculosis. J Infect Dis 2006;194:984–92.
16. Goletti D, Carrara S, Mayanja-Kizza H et al. Response to M. tuberculosis selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study. BMC Infect Dis 2008;8:11.
17. Demissie A, Leyten EM, Abebe M et al. Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clin Vaccine Immunol 2006;13:179–86.
18. Goletti D, Butera O, Vanini V et al. Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. Eur Respir J 2010;36:135–42.
19. Locht C, Hougardy JM, Rouanet C, Place S, Mascart F. Heparin-binding hemagglutinin, from an extrapulmonary dissemination factor to a powerful diagnostic and protective antigen against tuberculosis. Tuberculosis 2006;86:303–9.
20. Delogu G, Chiacchio T, Vanini V et al. Methylated HBHA produced in M. smegmatis discriminates between active and non-active tuberculosis disease among RD1-responders. PLoS ONE 2011;6:e1815.
21. Hougardy JM, Place S, Hildebrand M et al. Regulatory T cells depress immune responses to protective antigens in active tuberculosis. Am J Respir Crit Care Med 2007;176:409–16.
22. Hutchinson P, Barkham TM, Tang W, Kemeny DM, Chee CB, Wang YT. Measurement of phenotype and absolute number of circulating heparin-binding hemagglutinin, ESAT-6 and CFP-10, and purified protein derivative antigen-specific CD4 T cells can discriminate active from latent tuberculosis infection. Clin Vaccine Immunol 2015;22:200–12.
23. Wyndham-Thomas C, Dirix V, Schepers K et al. Contribution of a heparin-binding haemagglutinin interferon-gamma release assay to the detection of Mycobacterium tuberculosis infection in HIV-infected patients: comparison with the tuberculin skin test and the QuantiFERON-TB Gold In-tube. BMC Infect Dis 2015;15:59.
24. Temmerman ST, Place S, Debrie AS, Locht C, Mascart F. Effector functions of heparin-binding hemagglutinin-specific CD8 + T lymphocytes in latent human tuberculosis. J Infect Dis 2005;192:226–32.
25. van Pinxteren LA, Cassidy JP, Smedegaard BH, Agger EM, Andersen P. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur J Immunol 2000;30:3689–98.
26. Masungi C, Temmerman S, Van Vooren JP et al. Differential T and B cell responses against Mycobacterium tuberculosis heparin-binding hemagglutinin adhesin in infected healthy individuals and patients with tuberculosis. J Infect Dis 2002;185:513–20.
27. Molicotti P, Bua A, Cubeddu M, Cannas S, Delogu G, Zanetti S. Tuberculosis patients are characterized by a low-IFN-gamma/high-TNF-alpha response to methylated HBHA produced in M. smegmatis. Diagn Microbiol Infect Dis 2011;71:449–52.
28. Corbiere V, Pottier G, Bonkain F et al. Risk stratification of latent tuberculosis defined by combined interferon gamma release assays. PLoS ONE 2012;7:e43285.
29. Delogu G, Bua A, Pusceddu C et al. Expression and purification of recombinant methylated HBHA in Mycobacterium smegmatis. FEMS Microbiol Lett 2004;239:33–9.
30. Getahun H, Matteelli A, Abubakar I et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J 2015;46:1563–76.
31. Barry CE III, Boshoff HI, Dartois V et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009;7:845–55.
32. Andersen P, Doherty TM, Pai M, Weldingh K. The prognosis of latent tuberculosis: can disease be predicted? Trends Mol Med 2007;13:175–82.
33. Walzl G, Haks MC, Joosten SA, Kleynhans L, Ronacher K, Ottenhoff TH. Clinical immunology and multiplex biomarkers of human tuberculosis. Cold Spring Harb Perspect Med 2015;5: a018515.
34. Ayele HT, Mourik MS, Debray TP, Bonten MJ. Isoniazid prophylactic therapy for the prevention of tuberculosis in HIV infected adults: a systematic review and meta-analysis of randomized trials. PLoS ONE 2015;10:e0142290.
35. Goletti D, Parracino MP, Butera O et al. Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study. Respir Res 2007;8:5.
36. Biraro IA, Egesa M, Kimuda S et al. Effect of isoniazid preventive therapy on immune responses to mycobacterium tuberculosis: an open label randomised, controlled, exploratory study. BMC Infect Dis 2015;15:438.
37. Karam F, Mbow F, Fletcher H et al. Sensitivity of IFN-gamma release assay to detect latent tuberculosis infection is retained in HIV-infected patients but dependent on HIV/AIDS progression. PLoS ONE 2008;3:e1441.
38. Vanini V, Petruccioli E, Gioia C et al. IP-10 is an additional marker for tuberculosis (TB) detection in HIV-infected persons in a low-TB endemic country. J Infect 2012;65:49–59.
39. Lange C, van Leth F, Sester M. Viral load and risk of tuberculosis in HIV infection. J Acquir Immune Defic Syndr 2016;71:e51–3.
40. Temmerman S, Pethe K, Parra M et al. Methylation-dependent T cell immunity to Mycobacterium tuberculosis heparin-binding hemagglutinin. Nat Med 2004;10:935–41.
41. Parra M, Pickett T, Delogu G et al. The mycobacterial heparin-binding hemagglutinin is a protective antigen in the mouse aerosol challenge model of tuberculosis. Infect Immun 2004;72:6799–805.
42. Kohama H, Umemura M, Okamoto Y et al. Mucosal immunization with recombinant heparin-binding haemagglutinin adhesin suppresses extrapulmonary dissemination of Mycobacterium bovis bacillus Calmette-Guerin (BCG) in infected mice. Vaccine 2008;26:924–32.
43. Zhao S, Zhao Y, Mao F et al. Protective and therapeutic efficacy of Mycobacterium smegmatis expressing HBHA-hIL12 fusion protein against Mycobacterium tuberculosis in mice. PLoS ONE 2012;7:e31908.
44. Rouanet C, Debrie AS, Lecher S, Locht C. Subcutaneous boosting with heparin binding haemagglutinin increases BCG-induced protection against tuberculosis. Microbes Infect 2009;11:995–1001.
45. Belay M, Legesse M, Mihret A et al. IFN-gamma and IgA against non-methylated heparin-binding hemagglutinin as markers of protective immunity and latent tuberculosis: results of a longitudinal study from an endemic setting. J Infect 2016;72:189–200.
46. Zak DE, Penn-Nicholson A, Scriba TJ et al. A blood RNA signature for tuberculosis disease risk: a prospective cohort study. Lancet 2016;387:2312–22.
47. Fletcher HA, Snowden MA, Landry B et al. T-cell activation is an immune correlate of risk in BCG vaccinated infants. Nat Commun 2016;7:11290.